Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Slowing down ALS--is this good or bad?

T L Munsat1

  • 1Department of Neurology, New England Medical Center, Boston, MA 02111, USA.

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
|July 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase-locking of magnetic islands diagnosed by ECE-imaging.

The Review of scientific instruments·2014
Same author

Automated system for the analysis of muscle and nerve biopsies.

Applied optics·2010
Same author

Lead exposure as a risk factor for amyotrophic lateral sclerosis.

Neuro-degenerative diseases·2006
Same author

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2001
Same author

Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome.

Journal of the neurological sciences·2001
Same author

Dietary intake of calcium, magnesium and antioxidants in relation to risk of amyotrophic lateral sclerosis.

Neuroepidemiology·2000
Same journal

Dementia of frontal lobe type in Kennedy's disease.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
Same journal

Venous thrombosis in an ALS population over four years.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
Same journal

Spirometer-dependence of vital capacity in ALS: validation of a portable device in 52 patients.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
Same journal

A rare Cu/Zn superoxide dismutase mutation causing familial amyotrophic lateral sclerosis with variable age of onset and incomplete penetrance in China.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
Same journal

Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
Same journal

Psychopathology in amyotrophic lateral sclerosis: a preliminary study with 27 ALS patients.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2005
See all related articles

Riluzole offers modest relief for Amyotrophic Lateral Sclerosis (ALS) patients, providing a short-term quality of life and economic benefit. Despite its limitations, the drug highlights the ongoing need for further ALS therapies.

Area of Science:

  • Neurology
  • Pharmacology
  • Medical Ethics

Background:

  • Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease with limited treatment options.
  • The introduction of riluzole has presented new ethical and economic considerations for ALS management.

Purpose of the Study:

  • To evaluate the ethical and economic implications of riluzole in ALS treatment.
  • To assess the current benefits and limitations of riluzole for patients, caregivers, and physicians.

Main Methods:

  • Review of early evidence and clinical data on riluzole's efficacy.
  • Analysis of the quality of life and economic impact of riluzole therapy.

Main Results:

  • Riluzole provides modest symptomatic relief in ALS patients.

Related Experiment Videos

  • Evidence suggests a short-term improvement in quality of life and economic benefits for patients and society.
  • Riluzole does not alter the disease's progression or ultimate outcome.

    • Conclusions:

    • Riluzole offers a limited but valuable benefit in ALS management.
    • The current therapeutic landscape for ALS necessitates the development of additional treatment strategies.